This is a $5,721,770.90 definitive, cost-plus-fixed-fee contract awarded by the Defense Health Agency (DHA) to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer of medical countermeasures and pharmaceuticals. The contract is for the creation of an FDA-approved analgesic ketamine drug with an auto-injector delivery system. The award is not associated with a larger contract vehicle and does not have a set-aside designation. The contract has a period of performance through February 29, 2024. Emergent has received over $1.3 billion in prime federal contracts from HHS and Defense agencies since 2019, including a $704 million contract to develop filovirus treatments and a $6.9 million DHA contract to develop this analgesic ketamine drug.
Generated 2/19/25, 9:29 AM